AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...

In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers ...

In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to elevate the impact of your medical education efforts in the latest Medical ...

CHCR is a research centre offering healthcare communication consultancy, professional development and training including the first UK Postgraduate Certificate in Health Communications.